Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Files An 8-K Entry into a Material Definitive Agreement
On March5, 2019, Sarepta Therapeutics, Inc. (the Company) entered into an underwriting agreement (the Underwriting Agreement) with Goldman Sachs Co. LLC and Morgan Stanley Co. LLC (the Underwriters), relating to the public offering (the Offering) of 2,604,167 shares of the Companys common stock, $0.0001 par value per share (the Common Stock), at a price to the public of $144.00 per share (the Offering Price), less underwriting discounts and commissions. The net proceeds to the Company from the sale of the Common Stock, after deducting the underwriting discounts and commissions and other estimated offering expenses payable by the Company, will be approximately $365.3million. The Offering is expected to close on March7, 2019, subject to the satisfaction of customary closing conditions. The Company has also granted the Underwriters a 30-day option to purchase up to an additional 390,625 shares of Common Stock at the Offering Price, less underwriting discounts and commissions.
The Offering was made to the Companys effective shelf registration statement on Form S-3, as amended (File No.333-229934), including the prospectus dated February28, 2019, as supplemented by the prospectus supplement dated March5, 2019.
The foregoing is only a brief description of the terms of the Underwriting Agreement, does not purport to be a complete description of the rights and obligations of the parties thereunder, and is qualified in its entirety by reference to the Underwriting Agreement that is filed as Exhibit 1.1 to this Current Report on Form 8-K and incorporated by reference herein.The opinion of Ropes Gray LLP relating to the validity of the shares to be issued in the Offering is attached as Exhibit 5.1 to this Current Report on Form 8-K.
On March5, 2019, the Company issued a press release announcing the Offering and a press release announcing the pricing of the Offering. Copies of these press releases are attached hereto as Exhibits 99.1 and 99.2.
|Press release dated March5, 2019.|
Sarepta Therapeutics, Inc. Exhibit
EX-1.1 2 d721001dex11.htm EX-1.1 EX-1.1 Exhibit 1.1 2,…
To view the full exhibit click
About Sarepta Therapeutics, Inc. (NASDAQ:SRPT)
Sarepta Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others. The Company, through its platform technologies, targets a range of diseases and disorders through RNA-targeted mechanisms of action. The Company is also developing therapeutics using its technology for the treatment of drug-resistant bacteria and infectious, rare and other human diseases. The Company’s lead Duchenne Muscular Dystrophy (DMD) product candidate, Eteplirsen, is an antisense phosphorodiamidate morpholino oligomer (PMO) therapeutic in Phase III clinical development for the treatment of individuals with DMD having an error in the gene coding for dystrophin that is amenable to skipping exon 51.